Physicians' Academy for Cardiovascular Education

Transforming diabetes management in cardiology: Impact of novel therapies

Meeting report with video, highlights and slides of a PACE-CME symposium held during ESC 2019 in Paris on Transforming diabetes management in cardiology: Impact of novel therapies - videos and online CME will be added soon

Slides: 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases - Expert insights and rationale

Slides (presentation) - Oct. 7, 2019 - Prof Francesco Cosentino, MD, Stockholm, Sweden - CME symposium held during ESC 2019
This lecture by prof. Francesco Cosentino was part of a CME-accredited Expert on te Spot session

Slides as educational service to PACE members and meeting participants

Slides: The diabetes challenge for cardiologists: The key things to understand

Slides (presentation) - Oct. 7, 2019 - ESC Paris, France - Prof Naveed Sattar, Glasgow, UK
This lecture by prof. Naveed Sattar was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: Cardiac mechanisms of GLP-1 receptor agonists

Slides (presentation) - Oct. 7, 2019 - ESC Paris, France - Prof. Filip K. Knop, MD PhD, Copenhagen, Denmark - CME symposium held during ESC 2019
This lecture by prof. Filip K.Knop was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: The clinical perspectives of targeting GLP-1 RA: Where does it fit into CV risk management?

Slides (presentation) - Oct. 7, 2019 - ESC Paris, France - Prof. John E Deanfield, UCL, London, UK - CME symposium held during ESC 2019
This lecture by prof. John Deanfield was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD
Prof. Sattar shows that CV risk is heterogenous in patients with diabetes, and explains why new diabetes drugs, such as GLP-1RAs, are recommended for patients with diabetes and CV risk.

Prof. Sattar shows that CV risk is heterogenous in patients with diabetes, and explains why new diabetes drugs, such as GLP-1RAs, are recommended for patients with diabetes and CV risk.

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD
As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.

ESC 2019 As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.

Transforming diabetes management in cardiology: Impact of novel therapies
Transforming diabetes management in cardiology: Impact of novel therapies